Albany Molecular Research Inc. (NASDAQ:AMRI) shares saw an uptick in trading volume on Wednesday . 582,217 shares changed hands during trading, an increase of 76% from the previous session’s volume of 329,961 shares.The stock last traded at $15.07 and had previously closed at $15.01.

Separately, Morgan Stanley reaffirmed a “buy” rating on shares of Albany Molecular Research in a research report on Sunday, May 8th.

The firm’s 50-day moving average price is $14.41 and its 200 day moving average price is $14.68. The firm’s market cap is $519.66 million.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.04. The company had revenue of $116.50 million for the quarter, compared to analyst estimates of $123.10 million. Equities analysts predict that Albany Molecular Research Inc. will post $1.07 EPS for the current year.

In other Albany Molecular Research news, Director Kevin Oconnor sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $14.41, for a total transaction of $72,050.00. Following the sale, the director now owns 52,955 shares in the company, valued at approximately $763,081.55. The transaction was disclosed in a filing with the SEC, which is available through this link.

A hedge fund recently raised its stake in Albany Molecular Research stock. Ancora Advisors LLC raised its position in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 1.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,300 shares of the company’s stock after buying an additional 1,000 shares during the period. Ancora Advisors LLC owned approximately 0.30% of Albany Molecular Research worth $1,682,000 at the end of the most recent quarter.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.